The application of an LC-MS/MS method in a pharmacokinetic study for the determination of the concentration of nifekalant in human plasma.
In the present study, a simple, rapid, and accurate liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the determination of the concentration of Nifekalant in human plasma was developed and validated. The analyte and the internal standard were extracted from human plasma using dichloromethane and analyzed using an ultra-fast liquid chromatographer (UFLC) coupled to an electrospray ionization (ESI) tandem mass spectrometer in the positive mode. The chromatographic analysis was performed isocratically on an Inertsil ODS-SP column (150mm×4.6mm I.D., 5μm). The mobile phase was a mixture of 15% 10mM aqueous ammonium formate and 85% methanol (the pH was adjusted to 3.5 with formic acid) at a flow rate of 0.8mL/min with a split ratio of 1:1 to the ionization source. The lower limit of quantification (LLOQ) was 5.05ng/mL, and a linear calibration curve was obtained over the concentration range of 5.05 to 3030ng/mL. The intra-day and inter-day assay variations were less than 9.06%, and the accuracy values (relative error) were in the range of -10.95% to 2.27%. The essential pharmacokinetic parameters of the intravenously injection of Nifekalant were found to be the following: t1/2=1.26±0.16h,Cmax=1.943±0.411mg/L, and AUC0-12h=4.600±0.756mg/L·h.
Department of Pharmacy, General Hospital of Shenyang Military Area Command, No 83, Wenhua Road, Shenhe District, Shenyang, 110840, China.
Mengmeng
M
Zhang
Guobing
G
Shi
Yin
Y
Sui
Ye
Y
An
Ming
M
Yan
Yunbiao
Y
Tang
D000328:Adult; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D004355:Drug Stability; D005260:Female; D006801:Humans; D057230:Limit of Detection; D016014:Linear Models; D008297:Male; D011744:Pyrimidinones / Q000097:blood* / Q000737:chemistry / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D053719:Tandem Mass Spectrometry / Q000379:methods*
D011744:Pyrimidinones; C076259:nifekalant
LC-MS/MS; Nifekalant; Pharmacokinetics